# A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

> **NCT06783816** · NA · RECRUITING · sponsor: **Shanxi Bethune Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Acute Lymphocytic Leukemia
- Lymphoma,Non-Hodgkin
- Relapsed Refractory Multiple Myeloma

## Interventions

- **DRUG:** chimeric antigen receptor gene modified T cells

## Key facts

- **NCT ID:** NCT06783816
- **Lead sponsor:** Shanxi Bethune Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2028-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06783816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06783816, "A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06783816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*